

ASX Release

SUDA PHARMACEUTICALS LTD: APPENDIX 4C FOR THIRD QUARTER FY2018

PERTH, AUSTRALIA – 30 April 2018: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today released its Appendix 4C for the consolidated Group for the third quarter of FY2018.

During the quarter and as announced on 27 February 2018, SUDA sold its subsidiary company, Westcoast Surgical and Medical Supplies Pty Ltd. The sale price was \$1,736,266 of which \$1,686,266 was received in the reporting quarter.

SUDA also completed its acquisition of the intellectual property relating to anagrelide, an anti-thrombotic that has shown promise as a novel anti-cancer agent.

Section 9 of the Appendix 4C outlines our estimated cash outflows for the next quarter at \$745,000. As at 31 March 2018, SUDA had net cash of \$1.0 million.

SUDA's Executive Chairman and CEO, Mr Stephen Carter, commented: "The divestment of Westcoast Surgical and Medical Supplies has strengthened our balance sheet as we look to finalise our next commercial deals. I am pleased with the progress we are making towards these and other goals and anticipate achieving some significant milestones in the next couple of months."



Further information:
STEPHEN CARTER
EXECUTIVE CHAIRMAN
SUDA Pharmaceuticals Ltd
Tel: +61 8 6142 5555
sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit www.sudapharma.com

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Name of entity

Suda Pharmaceuticals Ltd

ABN

35 090 987 250

Quarter ended ("current quarter")

31 March 2018

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	1,053	5,043
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(1,044)	(3,689)
(c) advertising and marketing	-	-
(d) leased assets	(5)	(16)
(e) staff costs	(617)	(1,669)
(f) administration and corporate costs	(482)	(2,326)
1.3 Dividends received (see note 3)	-	
1.4 Interest received	-	2
1.5 Interest and other costs of finance paid	(20)	(66)
1.6 Income taxes paid	-	
1.7 Government grants and tax incentives	-	663
1.8 Other (provide details if material)	-	
1.9 Net cash from / (used in) operating activities	(1,115)	(2,058)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	(33)	(68)
(b) businesses (see item 10)	-	-
(c) investments	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
(d) intellectual property	(185)	(552)
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	1,686	1,686
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	1,468	1,066

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	200
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	550	550
3.6 Repayment of borrowings	(550)	(550)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	-	200

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	625	1,770
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(1,115)	(2,058)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	1,468	1,066
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	200
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of quarter	978	978

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	978	625
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	978	625

6.	Payments to directors of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to these parties included in item 1.2	152
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B

7. Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (Convertible Notes)	2,002	2,002
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

The Company had on issue 2,002,500 secured convertible notes with a face value of \$1 each. The interest rate was 8% pa, the maturity date is 31 March 2019 and conversion price is \$0.0238.

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	-
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	4
9.5 Staff costs	350
9.6 Administration and corporate costs	340
9.7 Other (provide details if material)	51
9.8 Total estimated cash outflows	745

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		Westcoast Surgical and Medical Supplies Pty Ltd
10.2 Place of incorporation or registration		Osborne Park, Western Australia
10.3 Consideration for acquisition or disposal		\$1,736,266
10.4 Total net assets		\$790,772
10.5 Nature of business		Distribution of medical devices and consumables

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here:
(Director/Company secretary)

Date: 30 April 2018.....

Print name:Stephen Carter.....

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.